Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. UPLIZNA (inebilizumab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

UPLIZNA (inebilizumab)

Medicine - Posted on Jun 01 2023
Active substance (DCI)
  • inebilizumab
history (3)
  • 5/24/23

    UPLIZNA (inébilizumab) - Neuromyélite optique

    Autorisation d’accès précoce renouvelée à la spécialité UPLIZNA (inébilizumab) dans l'indication « en monothérapie dans le t...
    icône flèche
  • 10/19/22

    UPLIZNA (inébilizumab) - Neuromyélite optique

    Key points Approval of reimbursement as monotherapy for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in ...
    CAV :
    54321
    icône flèche
  • 5/25/22

    UPLIZNA (inebilizumab) - maladies du spectre de la neuromyélite optique (NMOSD)

    Autorisation d’accès précoce octroyée à la spécialité UPLIZNA (inebilizumab) dans l'indication « en monothérapie dans le tra...
    icône flèche
Technical information
ATC code
  • L04AA47
Manufacturer
INTSEL CHIMOS
Presentation

UPLIZNA 100 mg, solution à diluer pour perfusion
Conditionnement de 3 flacons x 10 mL (CIP : 34009 550 891 4 8)

All our publications
    Anemia and hemoglobinopathies Congenital, genetic and rare diseases Drug therapy Metabolic diseases Paediatrics Respiratory tract cancers Urologic diseases - miscellaneous

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
TZBneEHhSWcGLfD4